BC
KYMR icon

Brookfield Corp’s Kymera Therapeutics KYMR Stock Holding History

Brookfield Corp’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29,215
Closed -$1.24M – 684
2022
Q1 		$1.24M Buy
29,215
+8,719
+43% +$368K ﹤0.01% 470
2021
Q4 		$1.3M Buy
20,496
+2,931
+17% +$171K 0.01% 399
2021
Q3 		$1.03M Buy
+17,565
New +$1.02M ﹤0.01% 413

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Brookfield Corp's KYMR Position: Q2 2022 in Review

Brookfield Corp sold out of Kymera Therapeutics (KYMR) in Q2 2022, closing a stake of 29,215 shares — an estimated $1.24M sold.

Brookfield Corp first reported a position in KYMR in Q3 2021 and held it in 3 quarters. The position peaked at $1.3M in Q4 2021. 100 funds tracked by Wall St. Rank hold KYMR as of Q2 2022.

  • Brookfield Corp reported no remaining Kymera Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Brookfield Corp sold 29,215 Kymera Therapeutics shares in Q2 2022, an estimated $1.24M.
  • Brookfield Corp first reported a position in Kymera Therapeutics in Q3 2021 and held it in 3 quarters.
  • Brookfield Corp's Kymera Therapeutics position peaked at $1.3M in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2022.

Based on Brookfield Corp's 13F filing for Q2 2022, filed 15 Aug 2022.